ACCURAY INCORPORATED (NASDAQ:ARAY) Files An 8-K Regulation FD Disclosure

ACCURAY INCORPORATED (NASDAQ:ARAY) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

Story continues below

ACCURAY INC Exhibit
EX-99.1 2 aray-ex991_6.htm EX-99.1 aray-ex991_6.htm   EXHIBIT 99.1           Accuray To Discuss Revenue Growth Expectations for the Next Three Fiscal Years at the JP Morgan Healthcare Conference   Company to present on Wednesday,…
To view the full exhibit click here

About ACCURAY INCORPORATED (NASDAQ:ARAY)

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

An ad to help with our costs